Veerhealth Care (BSE 511523)₹51.42+4.68%Pharmaceuticals
In the Mar 2026 quarter (standalone), Veerhealth Care reported sales of ₹16.78 Cr, up 198.0% from Mar 2025, and net profit of −₹0.36 Cr. For the year to Mar 2026, sales were ₹32.51 Cr and net profit ₹0.55 Cr.
Company filings, standalone accounts; latest reported quarter Mar 2026
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3.59 | 3.84 | 2.88 | 3.38 | 2.07 | 5.16 | 3.85 | 5.63 | 4.50 | 3.99 | 7.27 | 16.78 |
| Expenses | 3.16 | 3.63 | 2.71 | 3.21 | 2.09 | 4.68 | 3.70 | 5.79 | 4.53 | 3.46 | 6.03 | 16.05 |
| Operating Profit | 0.42 | 0.20 | 0.16 | 0.16 | −0.01 | 0.47 | 0.14 | −0.15 | −0.02 | 0.52 | 1.23 | 0.72 |
| OPM % | 12.0% | 5.5% | 5.9% | 5.1% | −1.0% | 9.4% | 3.9% | −2.9% | −0.7% | 13.3% | 17.1% | 4.4% |
| Other Income | 0.14 | 0.41 | 0.23 | 0.16 | 0.35 | 0.24 | 0.17 | 0.42 | 0.64 | 0.22 | −0.28 | −0.08 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.10 | 0.00 | 0.13 | 0.09 | 0.09 | 0.09 | 0.10 |
| Depreciation | 0.19 | 0.19 | 0.19 | 0.19 | 0.20 | 0.21 | 0.26 | 0.27 | 0.29 | 0.32 | 0.36 | 0.36 |
| Profit before tax | 0.41 | 0.46 | 0.24 | 0.17 | 0.16 | 0.43 | 0.08 | −0.14 | 0.25 | 0.36 | 0.51 | 0.19 |
| Tax % | 15.0% | 13.3% | 17.4% | 443.7% | 20.0% | 28.6% | 0.0% | −23.1% | 0.0% | 25.7% | 18.0% | 294.4% |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Profit | 0.35 | 0.40 | 0.20 | −0.56 | 0.13 | 0.31 | 0.08 | −0.11 | 0.25 | 0.26 | 0.41 | −0.36 |
| EPS (Rs) | 0.16 | 0.19 | 0.09 | −0.27 | 0.05 | 0.14 | 0.03 | −0.04 | 0.13 | 0.12 | 0.21 | −0.17 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2.15 | 1.90 | 5.18 | 5.99 | 11.73 | 10.63 | 9.66 | 13.30 | 13.23 | 16.70 | 32.51 | 32.54 |
| Expenses | 2.17 | 2.26 | 5.30 | 5.55 | 11.05 | 10.59 | 10.47 | 12.81 | 12.63 | 16.24 | 30.07 | 30.07 |
| Operating Profit | −0.01 | −0.35 | −0.11 | 0.43 | 0.67 | 0.05 | −0.81 | 0.49 | 0.60 | 0.45 | 2.45 | 2.45 |
| OPM % | −0.9% | −19.1% | −2.3% | 7.4% | 5.8% | 0.6% | −8.5% | 3.8% | 4.6% | 2.8% | 7.6% | 7.5% |
| Other Income | 0.37 | 0.71 | 0.71 | 0.28 | 0.47 | 1.19 | 1.66 | 1.23 | 1.38 | 1.21 | 0.48 | 0.50 |
| Interest | 0.12 | 0.09 | 0.06 | 0.02 | 0.18 | 0.21 | 0.08 | 0.00 | 0.00 | 0.25 | 0.39 | 0.37 |
| Depreciation | 0.22 | 0.24 | 0.28 | 0.33 | 0.33 | 0.48 | 0.53 | 0.63 | 0.72 | 0.92 | 1.30 | 1.33 |
| Profit before tax | 0.03 | 0.04 | 0.27 | 0.39 | 0.66 | 0.58 | 0.25 | 1.13 | 1.29 | 0.52 | 1.27 | 1.31 |
| Tax % | 100.0% | 33.3% | 42.3% | 57.8% | 50.7% | 35.1% | 129.2% | −41.1% | 68.7% | 23.5% | 56.3% | — |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Profit | 0.02 | 0.03 | 0.15 | 0.17 | 0.33 | 0.39 | −0.08 | 1.59 | 0.42 | 0.40 | 0.55 | 0.56 |
| EPS (Rs) | 0.02 | 0.00 | 0.09 | 0.13 | 0.22 | 0.26 | −0.06 | 0.78 | 0.20 | 0.19 | 0.26 | 0.29 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 6.93 | 6.92 | 6.93 | 6.92 | 6.92 | 6.91 | 6.92 | 6.92 | 9.99 | 20.01 | 19.98 | 19.95 |
| Reserves | 5.88 | 5.90 | 5.94 | 6.17 | 6.36 | 6.83 | 7.12 | 7.01 | 11.45 | 1.85 | 2.23 | 2.93 |
| Borrowings | 1.02 | 1.09 | −0.17 | 1.22 | 0.95 | 2.49 | 1.74 | 0.00 | 0.00 | 0.00 | 4.92 | 4.59 |
| Other Liabilities | 0.24 | 0.23 | 0.37 | 0.42 | 1.95 | 1.77 | 2.98 | 6.23 | 3.84 | 6.31 | 6.69 | 16.75 |
| Total Liabilities | 14.07 | 14.14 | 13.07 | 14.73 | 16.18 | 18.00 | 18.76 | 20.16 | 25.28 | 28.17 | 33.82 | 44.22 |
| Fixed Assets | 2.08 | 2.70 | 2.51 | 5.53 | 5.47 | 9.44 | 9.49 | 10.53 | 12.02 | 11.98 | 19.88 | 23.42 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.23 | 2.18 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 11.99 | 11.44 | 10.56 | 8.97 | 8.53 | 8.56 | 9.27 | 9.63 | 13.26 | 16.19 | 13.94 | 20.80 |
| Inventories | 0.47 | 1.13 | 1.54 | 0.95 | 0.85 | 1.24 | 1.67 | 2.13 | 2.62 | 1.41 | 2.45 | 4.46 |
| Trade receivables | 0.92 | 0.88 | 0.60 | 0.91 | 0.73 | 0.93 | 1.53 | 1.53 | 1.83 | 3.91 | 3.20 | 9.70 |
| Cash & equivalents | 0.10 | 0.09 | 0.01 | 0.07 | 0.17 | 0.01 | 0.09 | 0.39 | 3.60 | 0.23 | 1.15 | 0.45 |
| Total Assets | 14.07 | 14.14 | 13.07 | 14.73 | 16.18 | 18.00 | 18.76 | 20.16 | 25.28 | 28.17 | 33.82 | 44.22 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | −3.74 | 0.00 | 1.70 | 1.77 | 1.99 | −0.37 | 1.01 | 1.82 | −0.71 | 2.91 | −0.40 | 4.20 |
| Cash from investing activity | 3.83 | 0.00 | −0.43 | −3.01 | −1.89 | −1.66 | −0.08 | −1.08 | −1.78 | −0.27 | −8.17 | −4.42 |
| Cash from financing activity | 0.00 | 0.00 | −1.32 | 1.30 | 0.01 | 1.84 | −0.82 | −0.41 | 5.68 | −5.98 | 9.51 | −0.45 |
| Net cash flow | 0.11 | 0.00 | −0.07 | 0.05 | 0.09 | −0.16 | 0.08 | 0.29 | 3.20 | −3.36 | 0.91 | −0.69 |
| Capex | 0.00 | 0.77 | 0.04 | 3.55 | 2.20 | 2.13 | 0.51 | 1.59 | 2.10 | 0.84 | 8.83 | 4.87 |
| Free cash flow | −1.03 | −0.77 | 1.67 | −1.79 | −0.22 | −2.49 | 0.51 | 0.24 | −2.80 | 2.23 | −9.22 | −0.68 |
| CFO / OP % | 2,533.0% | 50.0% | −253.0% | −1,550.0% | 480.0% | −44.0% | 2,050.1% | −225.9% | −99.9% | 523.1% | −65.0% | 179.1% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor days | 255 | 152 | 118 | 65 | 45 | 29 | 53 | 58 | 51 | 108 | 70 | 109 |
| Inventory days | 229 | 443 | 476 | 92 | 77 | 53 | 75 | 102 | 102 | 55 | 77 | 66 |
| Days payable | 56 | 33 | 70 | 20 | 146 | 38 | 43 | 113 | 23 | 87 | 85 | 184 |
| Cash conversion cycle | 431 | 565 | 527 | 141 | −21 | 48 | 88 | 50 | 133 | 79 | 66 | −5 |
| Working capital days | 2,121 | 1,049 | 1,597 | 394 | 9 | 145 | 177 | 128 | 158 | 289 | 135 | 51 |
| ROCE % | −0.2% | 1.1% | 1.0% | 2.5% | 2.9% | 5.5% | 5.0% | 2.2% | 6.3% | 6.0% | 3.2% | 7.2% |
For the Mar 2026 quarter, Veerhealth Care reported sales of ₹16.78 Cr, up 198.0% year on year and net profit of −₹0.36 Cr. The operating margin was 4.4%.
Veerhealth Care's sales for the year to Mar 2026 were ₹32.51 Cr; over the last twelve months they were ₹32.54 Cr.
Net profit for the year to Mar 2026 was ₹0.55 Cr, and ₹0.56 Cr over the last twelve months. Earnings per share over the same trailing period were ₹0.29.
Veerhealth Care reported borrowings of ₹4.59 Cr at Mar 2026, against cash and equivalents of ₹0.45 Cr.
Cash from operations was ₹4.20 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹0.68 Cr.